Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Second allogeneic hematopoietic stem cell transplantation as treatment forleukemia relapsing following a first transplant
Autore:
Blau, IW; Basara, N; Bischoff, M; Gunzelmann, S; Romer, E; Kirsten, D; Schmetzer, B; Kiehl, MG; Fauser, AA;
Indirizzi:
Clin Bone Marrow Transplantat & Hematol Oncol, D-55743 Idar Oberstein, Germany Clin Bone Marrow Transplantat & Hematol Oncol Idar Oberstein GermanyD-55743
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 1, volume: 25, anno: 2000,
pagine: 41 - 45
SICI:
0268-3369(200001)25:1<41:SAHSCT>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; GRAFT-VERSUS-LEUKEMIA; 2ND; THERAPY; BLOOD;
Keywords:
second allogeneic bone marrow transplant; conditioning regimen; relapse rate; acute leukemia; disease-free survival;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Blau, IW Clin Bone Marrow Transplantat & Hematol Oncol, Dr Ottmar Kohler Str 2, D-55743 Idar Oberstein, Germany Clin Bone Marrow Transplantat & Hematol Oncol Dr Ottmar Kohler Str 2 Idar Oberstein Germany D-55743
Citazione:
I.W. Blau et al., "Second allogeneic hematopoietic stem cell transplantation as treatment forleukemia relapsing following a first transplant", BONE MAR TR, 25(1), 2000, pp. 41-45

Abstract

We report 27 patients with relapsed acute or chronic leukemia who under,vent a second hematopoietic stem cell transplant (HSCT) from a related or unrelated donor, Seventeen patients were diagnosed with acute myelogenous leukemia (AML), six with acute lymphocytic leukemia (ALL) and four with chronicmyeloid leukemia (CML). Ages ranged from 22 to 49 years (median 37); 13 patients were female and 14 male. Relapse was diagnosed between 1 and 45 months after the first HSCT. Sixteen patients who relapsed had received an autologous transplant initially and 11 an allogeneic transplant. Ten patients relapsed within 6 months and 17 patients later than 6 months. Chemotherapy was used as reinduction for relapse after HSCT in 16 patients who had received an autologous transplant and in three who had received an allogeneic transplant, since the latter did not respond to reduction of immunosuppressionto induce a graft-versus-leukemia (GVL) reaction, Five of these 19 patients (26%) achieved complete remission (CR), seven patients did not respond tochemotherapy and seven achieved a partial remission (PR). The stem cell source for the second HSCT included bone marrow (n = 12) and PBSC (n = 4) from genotypically identical unrelated donors, PBSC (n = 7) and bone marrow (n= 3) from related donors. Currently eight of the 27 patients are alive anddisease-free after the second HSCT, One patient is alive and disease-free after two allogeneic transplants (day +1538), eight patients, who relapsed after an autologous transplant followed by an allogeneic transplant (days +248 to +1140), acute myeloid leukaemia (n = 6) and chronic myeloid leukemia(n = 2) are alive and disease-free. The overall disease-free survival is 30% (8/27), The overall disease-free survival of autologous transplant patients subsequently undergoing an allogeneic transplant is 43% (P = 0.049). Itis suggested that a second HSCT is possible for patients with leukemia relapse following the first autologous transplant. A second transplant might also be offered to patients relapsing after the first allogeneic HSCT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 10:27:30